medigraphic.com

2004, Número 2

<< Anterior Siguiente >>

Rev Fac Med UNAM 2004; 47 (2)


Cáncer pulmonar (1ª. de 2 partes)

Sánchez ES, Franco TR, Flores ALJ, Zepeda MA

Idioma: Español
Referencias bibliográficas: 50
Paginas: 64-68
Archivo PDF: 64.43 Kb.


RESUMEN

En México, el cáncer de pulmón (CAP) es la primera causa de muerte por neoplasia, el factor de riesgo principal para el CAP es el tabaquismo ya que está presente en el 90% de los casos; adicionalmente, se han identificado polimorfismos enzimáticos que influyen en la eliminación y activación de xenobióticos encontrados en el humo del cigarro. El CAP tiene una gran variedad de presentaciones clínicas que dependen de la ubicación del tumor y de su estirpe histológica, entre ellas se encuentran signos y síntomas de vías respiratorias bajas, los síndromes paraneoplásicos, manifestaciones cutáneas y otras, que se manifiestan en diferentes etapas de la enfermedad. Para hacer el diagnóstico de esta enfermedad, es esencial realizar una historia clínica y exploración física completas las cuales pueden sugerir fuertemente la presencia de esta malignidad para proceder después de la utilización de métodos específicos como lo son la citología de esputo, biopsia, histoquímica e inmunohistoquímica. De acuerdo al tipo de celularidad encontrada y su clasificación es el pronóstico que el paciente tendrá así como el tipo de tratamiento que será empleado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Secretaría de Salud México; Mortalidad general y mortalidad general por sexos. 2000

  2. Secretaría de Salud México; Mortalidad hospitalaria según causa de defunción y grupos de edad, lista condensada por estados 2000.

  3. Medina F, Salazar M. Frecuencia y patrón cambiante del cáncer pulmonar en México. Sal Pub Méx 2000; 42: 333-336

  4. Medina F, Barrera R, Morales J, Echegoyen R, Chavarría J, Rébora F. Primary lung cancer in Mexico city: a report of 1,019 cases. Lung Cancer. 1996; 14: 185-193.

  5. Travis W. Pathology of lung cancer. Clin Chest Med 2002; 23: 65-81.

  6. American Cancer Society. Tobacco use. In American Cancer Society. Cancer facts & figures 2001. Atlanta, GA: American Cancer Society. 2001: 29-32

  7. Bilello K, Murin S, Matthay R. Epidemiology, etiology and prevention of lung cancer. Clin Chest Med 2002; 23: 1-25

  8. Stephen S. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002; 3: 461-469

  9. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91: 1194 - 1210.

  10. Schuller H, McGavin M, Orloff M, Riechert A, Porter B. Simultaneous exposure to nicotine and hyperoxia causes tumors in hamsters. Lab invest 1995; 73: 448-56.

  11. Tang D, Phillips DH, Stampfer M et al. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res 2001; 61: 6708-6712.

  12. Hanawalt PC. Controlling the efficiency of excision repair. Mutat Res 200; 485: 3-13.

  13. Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res 2000; 451: 39-51

  14. Norbury CJ, Hickson ID. Celular responses to DNA damage. Annu Rev Pharmacol Toxicol 2001; 41: 367-401

  15. Pegg AE. Repair of O6-alkylguanine by alkyltransferasas. Mutat Res 2000; 462: 83-100.

  16. Wei Q, Cheng L, Amos CL et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000; 92: 1764-1772.

  17. Chikako K, Akiko O, Taro S, Sanae F, Julian M H. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 2002; 37: 241-256.

  18. Chen S, Xue K, Xu L, Ma G, Wu J. Polymorphisms of the CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung carcinoma in Chinese population. Mutat Res 2001; 458: 41-47

  19. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53: 2994-2999.

  20. Hasset C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro amino acid variants. Hum Mol Genet 1994; 3: 421-428.

  21. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hidrolase and susceptibility to emphysema. Lancet 1997; 105: s791-799.

  22. To-Figueras J, Gene M, Gomez-Catalan J et al. Lung cancer susceptibility in relation to combined polymorphism of microsomal epoxide hydrolase and glutathione S-transferase P1. Cancer Lett 2001; 173:155-162.

  23. London SJ, Smart J, Daly AK. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among african-americans and caucasians in Los Angeles County. Lung Cancer 2000; 28: 147-155.

  24. Persson I, Johansson I, Lou YC et al. Genetic polymorphism of xenobiotics metabolizing enzimes among chinese lung cancer patients. Int J Cancer 1999; 81: 325-329.

  25. Yin L, Pu, Liu TY et al. Genetic polymorphism of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer 2001; 33: 133-141.

  26. Wu X, Gwyn K, Amos CI et al. The association of microsomal epoxide hrydolase polymorphisms and lung cancer risk in african-american and mexican-americans. Carcinogenesis 2001; 22: 923-928.

  27. Benhamou S, Reinikainen M, Bouchardy C et al. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 1998; 58: 5291-5293.

  28. Hunninghake GW, Gadek JE, Kawanami O et al. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol 1979; 97: 149-206.

  29. Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of myeloperoxydase 463G a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9:180-184.

  30. Cascorbi I, Henning S, Brockmoller J et al. Substantially reduced risk of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res 2000; 60: 644-649.

  31. Schabath MB, Spitz MR, Zhang X et al. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis 2000; 21: 1163-6.

  32. Misra RR, Tangrea JA, Virtamo J et al. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett 2001; 164: 161-167.

  33. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994; 344: 721-724.

  34. Wang D, Kreutzer DA, Essigmann JM. Mutagenecity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat Res 1998; 400: 99-115.

  35. Wistuba IJ, Lam S, Behrens C et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89: 1366-1372.

  36. Sekido Y, Fong KW, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998; 1378: F21-F59.

  37. Oliner JD. The role of p53 in cancer development. Sci Am 1994; Sept-Oct: 16-24.

  38. Robert C. Lung cancer: a review. Am J Health Syst Pharm 2002; 59: 611-642.

  39. Sarah B, Einat T, Nitsan M, Jonathn S. Cutaneous manifestations of internal malignancies. Clinics in dermatology 2001; 19: 290-297.

  40. Robert B, Peter M, Alejandro C. Paraneoplastic syndromes associated with bronchogenic carcinoma. Clin Chest Med 2002; 23:257-64

  41. Imura H, Matsukura S, Yamamoto H et al. Studies on ectopic ACTH-producing tumors: clinical and biochemic features of 30 cases. Cancer 1975; 35 (part 2): 1430-1437

  42. Jex RK, van Heerden JA, Carpenter PC et al. Ectopic ACTH syndrome: diagnosis and therapeutic aspects. Am J Surg 1985; 149: 276-282.

  43. Stewart PM, Gibson S, Crosby SR et al. ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol-Oxford 1994; 40: 199-204.

  44. Collichio FA, Woolf PD, Brower M. Management of patients with small call carcinoma end the syndrome of ectopic corticotropin secretion. Cancer 1994; 73:1361-1367.

  45. Delisle L, Boyer MJ, Warr D et al. Ectopic corticotropin syndrome and small cell carcinonoma of the lung: clinical features, outcome, and complications. Arch Intern Med 1993; 153: 746-752.

  46. Dimopoulos MA, Fernandez JF, Samaan NA et al. Paraneoplastic Cushing’s syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer 1992; 69: 66-71.

  47. Shepherd FA, Laskey J, Evans WK et al. Cushing’s syndrome associated with ectopic corticotropin production and small cell lung cancer. J Clin Oncol 1992 10: 21-27.

  48. Winquist EW, Laskey J, Crump M et al. Ketoconazole in the management of paraneoplastic Cushing’s syndrome secondary to ectopic adrenocorticotropin production. J Clin Ocol 1995; 13: 157-164.

  49. Graus F, Dalmau J, Rene R et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15: 2866-2872.

  50. List AF, Hainsworth JD, Davis BW et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1998; 4: 1191-1198.




2020     |     www.medigraphic.com